Publication & Citation Trends
Publications
0 total
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
Cited by 12
Semantic Scholar
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Cited by 0
Semantic Scholar
Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis. OA
Cited by 5
Semantic Scholar
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis OA
Cited by 79
Semantic Scholar
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol OA
Cited by 233
Semantic Scholar
National, centralised hospital datasets can inform clinical trial outcomes in prostate cancer: A pilot study in the STAMPEDE trial.
Cited by 0
Semantic Scholar
LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476) OA
Cited by 20
Semantic Scholar
Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).
Cited by 11
Semantic Scholar
Research Topics
Prostate Cancer Treatment and Research
(25)
Child and Adolescent Psychosocial and Emotional Development
(9)
Prostate Cancer Diagnosis and Treatment
(8)
Cancer, Lipids, and Metabolism
(8)
Radiopharmaceutical Chemistry and Applications
(7)
Affiliations
Ontario Institute for Cancer Research
University of Toronto
Western General Hospital
Cancer Research UK
Edinburgh Cancer Research